At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
ATG-010drug
Likely dose
ATG-010 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor
In Brief
A Phase 2 clinical trial evaluating ATG-010 for Relapse/Refractory Multiple Myeloma. Completed, enrolled 82 participants across 17 sites.
Detailed Summary
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with immunomodulatory agents and proteasome Inhibitors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapse/Refractory Multiple Myeloma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartSep 2019
Primary CompletionFeb 2022
TodayJul 2026
First PostedMay 9, 2019
Enrollment StartSep 2, 2019
Primary CompletionFeb 25, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.1 years ago
Interventions
ATG-010drug
ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle). Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)